Real-World Outcomes of Transcatheter Tricuspid Valve Replacement
JAMA · 12.05.2026 · 335 (18) · 1606
DOI: 10.1001/jama.2026.3446 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA, erschienen am 12.05.2026. Verfasst von Raj R Makkar und 41 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, California. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Tricuspid Valve, Tricuspid Valve Insufficiency, Endovascular Procedures. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Transcatheter tricuspid valve replacement (TTVR) demonstrated superior outcomes over medical therapy in patients with severe tricuspid regurgitation (TR) in the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device II (TRISCEND II) randomized clinical trial, and received regulatory approval in the US in 2024. Contemporary real-world data on its effectiveness and safety remain limited.
Objective
To evaluate 30-day clinical, echocardiographic, and health status outcomes of TTVR in real-world use. Design, Setting, and Population Retrospective cohort study of all consecutive patients who underwent TTVR in the US from February 2024 through March 2025 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients had symptomatic, severe TR despite optimal medical therapy and TTVR was deemed appropriate by a heart team. Statistical analysis was conducted from September 2025 to February 2026. Exposure Device-enabled TTVR. Main Outcomes and Measures Thirty-day event rates (all-cause death, stroke, bleeding, new cardiac implantable electronic device [CIED] implantation, heart failure hospitalizations), TR reduction, and changes in health status (New York Heart Association [NYHA] functional class and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) are reported. Subgroup analyses examined the impact of baseline CIED status on outcomes.
Results
Among 1034 attempted procedures at 82 centers (mean [SD] age, 77.1 [10.6] years; 69.1% female; 73.2% NYHA functional class III/IV), a valve was successfully implanted in 1017 patients (98.4%). Mild or less TR was achieved in 98.4% of patients post procedure and in 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%; stroke, 0.2%; bleeding, 7.9%; new CIED, 15.9% in CIED-naive patients; and heart failure hospitalization, 3.1%. There were significant improvements in NYHA functional class (class I/II, 82.7%; P < .001) and mean KCCQ-OS score (22.4 points; P < .001) from baseline to 30 days. There were no significant differences in 30-day mortality ( P = .47), heart failure hospitalization ( P > .99), and functional outcomes ( P = .55) when patients were stratified by baseline CIED status. Conclusions and Relevance Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR. Thirty-day outcomes are consistent with the TRISCEND II pivotal trial, demonstrating acceptable safety, near-complete TR elimination, and significant health status improvements in an older, comorbid population. Rates of new CIED implantation and bleeding were lower than randomized clinical trial experience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cedars-Sinai Medical Center, Los Angeles, California.
- Henry Ford Heart & Vascular Institute, Henry Ford Hospital, Detroit, Michigan.
- Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- Division of Cardiovascular Medicine, Stanford University/Stanford Health Care, Stanford, California.
- Piedmont Heart Institute, Piedmont Atlanta Hospital, Atlanta, Georgia.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Zitieren
APA
Makkar, R. R., Gupta, A., O'Neill, B. P., Lalani, C., Sharma, R. P., Yadav, P., Frisoli, T. M., Thourani, V., Makar, M., Eleid, M. F., Lee, J., Babaliaros, V. C., Haeffele, C., Bajwa, T. K., Flueckiger, P., Cubeddu, R. J., Davidson, L. J., Padang, R., Spinetto, P. V., …, & Davidson, C. J. (2026). Real-World Outcomes of Transcatheter Tricuspid Valve Replacement. JAMA, 335(18), 1606. https://doi.org/10.1001/jama.2026.3446
Vancouver
Makkar RR, Gupta A, O'Neill BP, Lalani C, Sharma RP, Yadav P, et al. Real-World Outcomes of Transcatheter Tricuspid Valve Replacement. JAMA. 2026;335(18):1606. doi:10.1001/jama.2026.3446
BibTeX
@article{Makkar2026,
author = {Makkar, Raj R and Gupta, Aakriti and O'Neill, Brian P and Lalani, Christina and Sharma, Rahul P and Yadav, Pradeep and Frisoli, Tiberio M and Thourani, Vinod and Makar, Moody and Eleid, Mackram F and Lee, James and Babaliaros, Vasilis C and Haeffele, Christiane and Bajwa, Tanvir K and Flueckiger, Peter and Cubeddu, Robert J and Davidson, Laura J and Padang, Ratnasari and Spinetto, Pedro Villablanca and Allaqaband, Suhail and Narang, Akhil and Williams, Mathew and Gleason, Patrick and Tang, Gilbert H L and Khera, Sahil and Vavalle, John P and Byku, Isida and Depta, Jeremiah P and Garcia, Santiago and Kapadia, Samir and Zajarias, Alan and Chanin, Jake M and Kodali, Susheel K and Herrmann, Howard C and Morse, M Andrew and Petrossian, George and Sivak, Joseph A and Hahn, Rebecca T and Song, Yang and Leon, Martin B and Yeh, Robert W and Davidson, Charles J},
title = {Real-World Outcomes of Transcatheter Tricuspid Valve Replacement},
journal = {JAMA},
year = {2026},
volume = {335},
number = {18},
pages = {1606},
doi = {10.1001/jama.2026.3446}
}
EUVIMED